StockNews.com Upgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Hold

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $1.91 on Wednesday. The stock’s 50-day moving average is $1.95 and its two-hundred day moving average is $2.96. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The firm has a market cap of $10.89 million, a price-to-earnings ratio of -0.40 and a beta of 0.29.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.